Eli Lilly And Stock Debt To Equity
| LLY Stock | 764.20 33.50 4.58% |
Eli Lilly and fundamentals help investors to digest information that contributes to Eli Lilly's financial success or failures. It also enables traders to predict the movement of Eli Stock. The fundamental analysis module provides a way to measure Eli Lilly's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eli Lilly stock.
Eli |
Eli Lilly and Company Debt To Equity Analysis
Eli Lilly's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, Eli Lilly and has a Debt To Equity of 0.0%. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers-General (which currently averages 0.0) industry. The debt to equity for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run Equity Valuation Now
Equity ValuationCheck real value of public entities based on technical and fundamental data |
| All Next | Launch Module |
Eli Fundamentals
| Return On Equity | 0.63 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 337.36 B | |||
| Shares Outstanding | 950.3 M | |||
| Shares Owned By Insiders | 0.10 % | |||
| Shares Owned By Institutions | 84.33 % | |||
| Price To Book | 34.75 X | |||
| Price To Sales | 10.99 X | |||
| Revenue | 28.54 B | |||
| Gross Profit | 21.91 B | |||
| EBITDA | 6.54 B | |||
| Net Income | 6.24 B | |||
| Total Debt | 15.35 B | |||
| Book Value Per Share | 11.83 X | |||
| Cash Flow From Operations | 7.26 B | |||
| Earnings Per Share | 6.40 X | |||
| Price To Earnings To Growth | 2.23 X | |||
| Number Of Employees | 39 K | |||
| Beta | 0.35 | |||
| Market Capitalization | 279.81 B | |||
| Total Asset | 48.81 B | |||
| Z Score | 10.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 48.81 B | |||
| Last Dividend Paid | 3.92 |
About Eli Lilly Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly and's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly and based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.